

8. Screening for Colorectal Cancer

RECOMMENDATION

Screening for colorectal cancer is recommended for all persons aged 50 and older with annual fecal occult blood testing (FOBT), or sigmoidoscopy (periodicity unspecified), or both (see *Clinical Intervention*). There is insufficient evidence to determine which of these screening methods is preferable or whether the combination of FOBT and sigmoidoscopy produces greater benefits than does either test alone. There is also insufficient evidence to recommend for or against routine screening with digital rectal examination, barium enema, or colonoscopy, although recommendations against such screening in average-risk persons may be made on other grounds (see *Clinical Intervention*). Persons with a family history of hereditary syndromes associated with a high risk of colon cancer should be referred for diagnosis and management (see *Clinical Intervention*).

Burden of Suffering

Colorectal cancer is the second most common form of cancer in the U.S. and has the second highest mortality rate, accounting for about 140,000 new cases and about 55,000 deaths each year.¹ An individual's lifetime risk of dying of colorectal cancer in the U.S. has been estimated to be 2.6%.² About 60% of patients with colorectal cancer have regional or distant metastases at the time of diagnosis.¹ Estimated 5-year survival is 91% in persons with localized disease, 60% in persons with regional spread, and only 6% in those with distant metastases.² The average patient dying of colorectal cancer loses 13 years of life.² In addition to the mortality associated with colorectal cancer, this disease and its treatment—surgical resection, colostomies, chemotherapy, and radiotherapy—can produce significant morbidity. Persons at highest risk of colorectal cancer include those with uncommon familial syndromes (i.e., hereditary polyposis and hereditary nonpolyposis colorectal cancer [HNPCC]) and persons with longstanding ulcerative colitis.^{3,4} Familial syndromes are estimated to account for 6% of all colorectal cancers,³ and various genetic mutations associated with these syndromes have been identified.^{4a} Other principal risk factors include a history of colorectal cancer or adenomas in a first-degree relative, a personal history of large adenomatous polyps or colorectal cancer, and a prior diagnosis of endometrial, ovarian, or breast cancer. In an analysis of two

large cohorts involving over 840,00 patient-years of follow-up, a family history of colorectal cancer was associated with a significant increase in risk in younger persons (1.7–4-fold increase between ages 40 and 60), but was not associated with a significantly increased risk in persons after age 60;^{4b} risk was higher in persons with more than one affected relative. The absolute increase in lifetime risk in persons with a family history was modest, however: an estimated cumulative incidence of colorectal cancer by age 65 of 4% vs. 3% in persons without a family history.^{4b} Diets high in fat or low in fiber may also increase the risk of colorectal cancer.³

Accuracy of Screening Tests

The principal screening tests for detecting colorectal cancer in asymptomatic persons are the digital rectal examination, FOBT, and sigmoidoscopy. Less frequently mentioned screening tests include barium enema and colonoscopy, which have been advocated primarily for high-risk groups. The digital rectal examination is of limited value as a screening test for colorectal cancer. The examining finger, which is only 7–8 cm long, has limited access even to the rectal mucosa, which is 11 cm in length. A negative digital rectal examination provides little reassurance that the patient is free of colorectal cancer because fewer than 10% of colorectal cancers can be palpated by the examining finger.³

A second screening maneuver is FOBT. The reported sensitivity and specificity of FOBT for detecting colorectal cancer in asymptomatic persons are 26–92% and 90–99%, respectively (usually based on two samples from three different stool specimens), with the widely varying estimates reflecting differences in study designs.^{5–10} Positive reactions on guaiac impregnated cards, the most common form of testing, can signal the presence of bleeding from premalignant adenomas and early-stage colorectal cancers. The guaiac test can also produce false-positive results, however. The ingestion of foods containing peroxidases,¹¹ and gastric irritants such as salicylates and other antiinflammatory agents,¹² can produce false-positive test results for neoplasia. Nonneoplastic conditions, such as hemorrhoids, diverticulosis, and peptic ulcers, can also cause gastrointestinal bleeding. FOBT can also miss small adenomas and colorectal malignancies that bleed intermittently or not at all.^{13,14} Other causes of false-negative results include heterogeneous distribution of blood in feces,¹⁵ ascorbic acid and other antioxidants that interfere with test reagents,¹⁶ and extended delay before testing stool samples.¹⁷

As a result, when FOBT is performed on asymptomatic persons, the majority of positive reactions are falsely positive for neoplasia. The reported positive predictive value among asymptomatic persons over age 50 is only about 2–11% for carcinoma and 20–30% for adenomas.^{6,5,9,18–20} As-

suming a false-positive rate of 1–4%, a person who receives annual FOBT from age 50 to age 75 has an estimated 45% probability of receiving a false-positive result.²¹ This large proportion of false-positive results is an important concern because of the discomfort, cost, and occasional complications associated with follow-up diagnostic tests, such as barium enema and colonoscopy.^{22,23} Rehydration of stored slides can improve sensitivity, but this occurs at the expense of specificity.²⁴ In one study, rehydration improved sensitivity from 81% to 92%, but it decreased specificity from 98% to 90% and lowered positive predictive value from 6% to 2%. Due to the high false-positive rate, about one third of the entire screened population of asymptomatic patients underwent colonoscopy for abnormal FOBT results within a 13-year period.⁵

Other tests have been proposed to improve the accuracy of screening for fecal occult blood. Current evidence is equivocal as to whether HemoQuant (SmithKline Diagnostics, Sunnyvale, CA), a quantitative measurement of hemoglobin in the stool, has better sensitivity or specificity than does qualitative FOBT.^{9,10,25–29} Recently developed hemoglobin immunoassays offer the promise of improved sensitivity and specificity but require further evaluation before being considered for routine screening.^{30,31}

The third screening test for colorectal cancer is sigmoidoscopy. Sigmoidoscopic screening in asymptomatic persons detects 1–4 cancers per 1,000 examinations.^{32,33} However, the sensitivity and diagnostic yield of sigmoidoscopy screening varies with the type of instrument: the rigid (25 cm) sigmoidoscope, the short (35 cm) flexible fiberoptic sigmoidoscope, or the long (60 cm) flexible fiberoptic sigmoidoscope. Since only 30% of colorectal cancers occur in the distal 20 cm of bowel, and less than half occur in or distal to the sigmoid colon,^{34–37} the length of the sigmoidoscope has a direct effect on case detection. The rigid sigmoidoscope, which has an average depth of insertion of about 20 cm^{38–44} and allows examination to just above the rectosigmoid junction,⁴⁵ can detect only about 25–30% of colorectal cancers. The 35-cm flexible sigmoidoscope, however, can visualize about 50–75% of the sigmoid colon and can detect about 50–55% of polyps. Longer 60-cm instruments have an average depth of insertion of 40–50 cm, reaching the proximal end of the sigmoid colon in 80% of examinations^{46,47} with the capability of detecting 65–75% of polyps and 40–65% of colorectal cancers^{48–52} Researchers have examined the feasibility of introducing a 105-cm flexible sigmoidoscope in the family practice setting,⁵³ but it is unclear whether the added length substantially increases the rate of detection of premalignant or malignant lesions. Barium enema studies have confirmed that some neoplasms within reach of the sigmoidoscope may not be seen on endoscopy.⁵⁴

Sigmoidoscopy can also produce false-positive results, primarily by detecting polyps that are unlikely to become malignant during the patient's

lifetime. Autopsy studies have shown that 10–33% of older adults have colonic polyps at death,⁵⁵ but only 2–3% have colorectal cancer.^{56–58} Depending on the type of adenomatous polyp, an estimated 5–40% eventually become malignant,⁵⁹ a process that takes an average of 10–15 years.^{60,61} It follows that the majority of asymptomatic persons with colonic polyps discovered on routine sigmoidoscopic examination will not develop clinically significant malignancy during their lifetime. For these persons, interventions that typically follow such a discovery (i.e., biopsy, polypectomy, frequent colonoscopy), procedures that are costly, anxiety-provoking, and potentially harmful, are unlikely to be of significant clinical benefit.

Other potential screening tests for colorectal cancer include colonoscopy and barium enema, which appear to have comparable accuracy. About 95% of colorectal cancers are within reach of the colonoscope, and the examination has an estimated 75–95% sensitivity in detecting lesions within its reach.^{20,21} Colonoscopy, which requires sedation and often involves the use of a hospital suite, is more expensive than other screening tests and has a higher risk of anesthetic and procedural complications. The estimated sensitivity and specificity of air-contrast barium enema in detecting lesions within its reach are about 80–95% and 90%, respectively, using subsequent diagnosis as a reference standard.²¹ Some retrospective studies have reported a higher sensitivity of barium enema for detecting colorectal cancer (about 90–96%)^{62,63} with pathologic diagnosis as the reference standard, but these estimates generally do not account for the selection bias introduced by the case-selection methods.

Effectiveness of Early Detection

Persons with early-stage colorectal cancer at the time of diagnosis appear to have longer survival than do persons with advanced disease.² Since there is little information on the extent to which lead-time and length biases (see Chapter ii) account for these differences, researchers in the U.S. and Europe launched large clinical trials in the late 1970s to collect prospective data on the effects of screening on colorectal cancer mortality.

Two of these trials^{5,6} examined the effect of routine FOBT on colorectal cancer mortality. A randomized controlled trial involving over 46,000 volunteers over age 50 found that the 13-year cumulative mortality from colorectal cancer was 33% lower among persons advised to undergo annual FOBT (5.9 deaths per 1,000) than among a control group that was not offered screening (8.8 deaths per 1,000).⁵ The report provided insufficient data, however, to determine to what extent observed differences in outcome were attributable to FOBT or to the large number of colonoscopies that were performed due to frequent false-positive FOBT. An analysis of the study data by other authors suggested that one third to one

half of the mortality reduction was due to “chance” selection of persons for colonoscopy,⁶⁴ but the assumptions in the analysis have been disputed by the authors.⁶⁵ Another controlled trial,⁶ which was not randomized, assigned over 21,000 patients to a control group that received a standard periodic health examination or to a study group that was also offered FOBT; both groups received sigmoidoscopy screening. Among new patients (first visit to the preventive medicine clinic), colorectal cancer mortality was 43% lower in the study group than in controls, a difference of borderline statistical significance ($p = 0.053$, one-tail), and there was no difference in outcomes among patients seen previously at the clinic. Recent case-control studies have also reported a 31–57% reduction in risk among persons receiving FOBT.^{66,67} Three large clinical trials of FOBT screening, currently under way in Europe, are expected to report their results in the coming years.^{7,68,69}

Recent case-control studies have provided important information on the effectiveness of sigmoidoscopy screening. The largest study found that 9% of persons who died of colorectal cancer occurring within 20 cm of the anus had previously undergone a rigid sigmoidoscopic examination, whereas 24% of persons in the control group had received the test.⁷⁰ The adjusted odds ratio of 0.41 (95% confidence interval, 0.25–0.69) suggested that sigmoidoscopy screening reduced the risk of death by 59% for cancers within reach of the sigmoidoscope. The investigators noted that the adjusted odds ratio for patients who died of more proximal colon cancers was 0.96. This finding added support to the hypothesis that the reduced risk of death from cancers within reach of the rigid sigmoidoscope was due to screening rather than to confounding factors. Another case-control study reported that the odds ratio for dying of colorectal cancer was 0.21 in screened subjects, and the benefit appeared to be limited to cancers within the reach of the sigmoidoscope.⁷¹

Older evidence of the effectiveness of sigmoidoscopy screening suffered from important design limitations. A randomized controlled trial of multiphasic health examinations, which included rigid sigmoidoscopy, reported that the study group had significantly lower incidence and mortality rates from colorectal cancer.^{72–74} A subsequent analysis of the data, however, revealed that the proportion of subjects receiving sigmoidoscopy and the rate of detection or removal of polyps were similar in both the study and control groups, thus suggesting little benefit from sigmoidoscopy.⁷⁵ Two large screening programs found that persons receiving periodic rigid sigmoidoscopy had less advanced disease and better survival from colon cancer than was typical of the general population.^{76–78} However, both studies lacked internal controls and used nonrandomized methods to select participants; other methodologic problems with these investigations are outlined in other reviews.^{75,79}

An important consideration in assessing the effectiveness of sigmoidoscopic screening is the potential iatrogenic risk associated with the procedure. Complications from sigmoidoscopy are relatively rare in asymptomatic persons but can be potentially serious. Perforations are reported to occur in approximately 1 of 1,000–10,000 rigid sigmoidoscopic examinations.^{20,21,32,80} Although there are fewer data available on flexible sigmoidoscopy, the complication rate appears to be less than or equal to that observed for rigid sigmoidoscopy. The reported risk of perforation from colonoscopy is about one in 500–3,000 examinations,^{5,81} and the risk of serious bleeding is 1 in 1,000.⁵ The estimated risk of perforation during barium enema is 1 in 5,000–10,000 examinations.⁸²

DR. RUPNATHJI (DR. RUPAK NATH)

screening examination may be adequate for low-risk individuals,⁸⁶ an approach being investigated in the United Kingdom.⁸⁷

Primary preventive measures to prevent colorectal cancer are currently under investigation. An association between colorectal cancer and dietary intake of fat and fiber has been demonstrated in a series of epidemiologic studies (see Chapter 59). Current evidence has not demonstrated that

whether the observed benefits were due to FOBT or to the effect of performing colonoscopy on a large proportion of the screened population. For sigmoidoscopy, a case-control study supports a strong association between regular screening and reduced colorectal cancer mortality from cancers within reach of the sigmoidoscope. This study was limited, however, by its small number of cases, potential selection biases, and inability to provide prospective evidence of benefit. There are additional concerns about the adverse effects, costs, and optimal frequency of screening. Studies that will help resolve these uncertainties are currently in progress; the final results of ongoing European FOBT trials will be unavailable for several years, however, and a large United States study⁹⁷ of FOBT and sigmoidoscopy screening will not be completed until the turn of the century.

An important limitation to the effectiveness of screening for colorectal cancer is the ability of patients and clinicians to comply with testing. Patients may not comply with FOBT for a variety of reasons,^{68,98} but compliance rates are generally higher than for sigmoidoscopy. Recent clinical trials report compliance rates of 50–80% for FOBT among volunteers,^{5–7,68,69} but lower rates (about 15–30%) have been reported in community screening programs.^{99–101} Although the introduction of flexible fiberoptic instruments has made sigmoidoscopy more acceptable to patients,¹⁰² the procedure remains uncomfortable, embarrassing, and expensive, and therefore many patients may be reluctant to agree to this test. A survey of patients over age 50 found that only 13% wanted to receive a sigmoidoscopy examination after being advised that they should receive the test; the most common reasons cited for declining the test were cost (31%), discomfort (12%), and fear (9%).¹⁰³ In a study in which sigmoidoscopy was recommended repeatedly, only 31% of participants consented to the procedure,^{72–74} but this study was performed during years when rigid sigmoidoscopy was common. Compliance rates as low as 6–12% have been reported. Studies suggest that physician motivation is a major determinant of patient compliance,^{104,105} and physicians may be reluctant to perform screening sigmoidoscopy on asymptomatic persons. It has been estimated that a typical family physician with 3,000 active patients (one third aged 50 or older) would have to perform five sigmoidoscopies daily to initially screen the population and two daily procedures for subsequent screening.³³ In addition, examinations using 60-cm sigmoidoscopes are more time-consuming^{35–39} and require more extensive training^{106–108} than do those using shorter instruments.

Another limitation to screening is its cost. Although a formal cost-effectiveness analysis of screening for colorectal cancer is beyond the scope of this chapter, the economic implications associated with the widespread performance of FOBT and sigmoidoscopy are clearly significant. A single flexible sigmoidoscopic examination costs between \$100 and \$200.^{22,109} A policy

of routine FOBT and sigmoidoscopic screening of all persons in the United States over age 50 (about 63 million persons) would cost over \$1 billion per year in direct charges.¹⁰⁹ Others have calculated that FOBT screening alone could cost the United States and Canada between \$500 million and \$1.2 billion each year.^{110,111} Another model predicted that performing annual FOBT on persons over age 65 would cost about \$35,000 per year of life saved; adding flexible sigmoidoscopy would increase the cost to about \$42,000 to \$45,000 per year of life saved.¹¹² Mathematical models suggest that barium enema screening every 3–5 years might have comparable or superior cost-effectiveness when compared with sigmoidoscopy screening, but neither the clinical effectiveness nor acceptability of barium enema screening has been demonstrated directly in clinical studies.

The downstream effects of screening are also of concern. The logistical difficulties and costs of performing FOBT and sigmoidoscopy on a large proportion of the U.S. population are significant, due to the limited acceptability of the tests and the expense of performing screening and follow-up on a large proportion of the population. Moreover, the tests have potential adverse effects that must be considered, such as false-positive results that lead to expensive and potentially harmful diagnostic procedures. Studies that have reported reduced mortality from FOBT used rehydrated slides to increase sensitivity, thereby producing a higher proportion of false-positive results than with nonrehydrated slides; 32% of the annually screened population underwent colonoscopy during a 13-year follow-up period.⁶⁵ If this rate is extrapolated to the 63 million Americans over age 50 who would receive annual FOBT, it can be predicted that about 20 million persons would require colonoscopy.

The full implications of this “screening cascade” need to be considered, along with the scientific evidence of clinical benefits, before reaching conclusions about appropriate public policy. For example, using nonrehydrated slides rather than rehydrated slides could substantially reduce the adverse effects and costs of a national screening program. As noted earlier, data from a major screening trial suggest that using nonrehydrated slides rather than rehydrated slides could increase the positive predictive value of FOBT from 2% to 6%, subjecting far fewer screened persons to unnecessary colonoscopy. This improvement in specificity, however, comes at the expense of sensitivity, which decreased from 92% with rehydration to 81% in nonrehydrated slides. The use of nonrehydrated slides would therefore allow a much larger proportion of persons with cancer to escape detection.

The special considerations that apply to persons at increased risk of colorectal cancer are complicated by inadequate epidemiologic and effectiveness data and inconsistent disease classifications. Having a single family member with colorectal cancer does not carry the high risk associated with hereditary cancer syndromes (e.g., familial polyposis, HNPCC).^{4,113} A fam-

ily history that is suggestive of the latter includes a pattern of diagnoses consistent with autosomal dominant inheritance of a highly penetrant disorder. Characteristic features include a family history of colorectal cancer being diagnosed at an early age, frequent cases of multiple primary cancers, or florid adenomatous colonic polyps. Performing periodic colonoscopy to screen for cancer in these groups may be justified in light of the high risk of disease and the incidence of proximal colonic lesions, but there is no direct evidence to determine the optimal strategy in this population.

CLINICAL INTERVENTION

Screening for colorectal cancer is recommended for all persons aged 50 or over ("B" recommendation). Effective methods include FOBT and sigmoidoscopy. There is insufficient evidence to determine which of these screening methods is preferable or whether the combination of FOBT and sigmoidoscopy produces greater benefits than either test alone. Although there is good evidence to support FOBT on an annual basis, there is insufficient evidence to recommend a periodicity for sigmoidoscopy screening. A frequency of every 3–5 years has been recommended by other groups on the basis of expert opinion, and a well-designed case-control study suggests that protection remains unchanged for at least 10 years after rigid sigmoidoscopy. Current evidence suggests that at least some of the benefits of FOBT in reducing colorectal cancer mortality may be achieved through colonoscopic evaluation of abnormal results. Widespread FOBT or sigmoidoscopy screening is therefore likely to generate substantial direct and indirect costs. Appropriate public policy may require consideration of factors other than the scientific evidence of clinical benefit. The appropriate age to discontinue screening has not been determined.

Patients who are offered these tests should receive information about the potential benefits and harms of the procedures, the probability of false-positive results, and the nature of the tests that will be performed if an abnormality is detected. FOBT screening should adhere to current guidelines for dietary restrictions, sample collection, and storage. Although slide rehydration increases the sensitivity of FOBT, it also decreases specificity, and there is insufficient evidence to determine whether rehydration results in better outcomes than screening with nonrehydrated slides. Sigmoidoscopy should be performed by a trained examiner. The instrument should be selected on the basis of examiner expertise and patient comfort. Longer (e.g., 60-cm instrument) flexible sigmoidoscopes have greater sensitivity and are more comfortable than shorter, rigid sigmoidoscopes.

There is insufficient evidence to recommend for or against routine screening with digital rectal examination, barium enema, or colonoscopy

("C" recommendation). Recommendations against using these tests for screening average-risk persons may be made on other grounds (e.g., availability of alternate tests of proven effectiveness, inaccuracy of digital rectal examination, costs and risks of colonoscopy).

In persons with a single first-degree relative with colon cancer, it is not clear that the modest increase in the absolute risk of cancer justifies routine use of colonoscopy over other screening methods. The increased risk of developing cancer at younger ages may justify beginning screening before age 50 in persons with a positive family history, however, especially when affected relatives developed colorectal cancer at younger ages. Direct evidence of the benefit of screening in younger persons is not available for any group. For persons with a family history of hereditary syndromes associated with a very high risk of colon cancer (i.e., familial polyposis or HNPCC), as well as those previously diagnosed with ulcerative colitis, high-risk adenomatous polyps, or colon cancer, regular endoscopic screening is part of routine diagnosis and management; referral to specialists is appropriate for these high-risk patients.

The draft update of this chapter was prepared for the U.S. Preventive Services Task Force by Steven H. Woolf, MD, MPH.

REFERENCES

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. *CA Cancer J Clin* 1995;45:8-30.
2. Ries LAG, Miller BA, Hankey BF, et al, eds. SEER cancer statistics review, 1973-1991: tables and graphs. Bethesda: National Cancer Institute, 1994. (NIH Publication no. 94-2789.)
3. Winawer SJ, Shike M. Prevention and control of colorectal cancer. In: Greenwald P, Kramer BS, Weed DL, eds. *Cancer prevention and control*. New York: Marcel Dekker, 1995:537-559.
4. Rustgi AK. Hereditary gastrointestinal polyposis and nonpolyposis syndromes. *N Engl J Med* 1994;331:1694-1702.
- 4a. Toribara NW, Sleisenger MH. Screening for colorectal cancer. *N Engl J Med* 1995;332:861-867.
- 4b. Fuchs CS, Giovannucci EL, Colditz GA, et al. A prospective study of family history and the risk of colorectal cancer. *N Engl J Med* 1994;331:1669-1674.
5. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. *N Engl J Med* 1993;328:1365-1371.
6. Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. *J Natl Cancer Inst* 1993;85:1311-1318.
7. Kewenter J, Asztely M, Engaras B, Haglind E, Svanvik J, Ahren C. A randomised trial of faecal occult blood testing for early detection of colorectal cancer: results of screening and rescreening of 51,325 subjects. In: Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC, eds. *Cancer screening*. Cambridge, England: Cambridge University Press, 1991:117-125.
8. Thomas WM, Pye G, Hardcastle JD, Walker AR. Screening for colorectal carcinoma: an analysis of the sensitivity of Haemocult. *Br J Surg* 1992;79:833-835.
9. Ahlquist DA, Wieland HS, Moertel CG, et al. Accuracy of fecal occult blood screening for colorectal neoplasia: a prospective study using Hemocult and HemoQuant tests. *JAMA* 1993;269:1262-1267.
10. St John DJB, Young GP, McHutchison JG, Deacon MC, Alexeyeff MA. Comparison of the specificity and sensitivity of Hemocult and HemoQuant in screening for colorectal neoplasia. *Ann Intern Med* 1992;117:376-382.
11. Illingworth DG. Influence of diet on occult blood tests. *Gut* 1965;6:595-598.
12. Rees WD, Turnberg LA. Reappraisal of the effects of aspirin on the stomach. *Lancet* 1980;2:410-413.

13. Crowley ML, Freeman LD, Mottet MD, et al. Sensitivity of guaiac-impregnated cards for the detection of colorectal neoplasia. *J Clin Gastroenterol* 1983;5:127-130.
14. Griffith CDM, Turner DJ, Saunders JH. False-negative results of Hemoccult test in colorectal cancer. *BMJ* 1981;283:472.
15. Rosenfield RE, Kochwa S, Kaczera Z, et al. Nonuniform distribution of occult blood in feces. *Am J Clin Pathol* 1979;71:204-209.
16. Jaffe RM, Kasten B, Young DS, et al. False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C). *Ann Intern Med* 1975;83:824-826.
17. Morris DW, Hansell JR, Ostrow D, et al. Reliability of chemical tests for fecal occult blood in hospitalized patients. *Dig Dis* 1976;21:845-852.
18. Windeler J, Kobberling J. Colorectal cancer and Haemoccult. A study of its value in mass screening using meta-analysis. *Int J Colon Dis* 1987;2:223-228.
19. Bang KM, Tillett S, Hoar SK, et al. Sensitivity of fecal Hemoccult testing and flexible sigmoidoscopy for colorectal cancer screening. *J Occup Med* 1986;28:709-713.
20. Winawer SJ, Schottenfeld D, Flehinger BJ. Colorectal cancer screening. *J Natl Cancer Inst* 1991;83:243-253.
21. Eddy DM, Ferioli C, Anderson DS. Screening for colorectal cancer. *Ann Intern Med* 1996 (in press).
22. Brandeau ML, Eddy DM. The workup of the asymptomatic patient with a positive fecal occult blood test. *Med Decis Making* 1987;7:32-46.
23. Lieberman DA. Colon cancer screening: the dilemma of positive screening tests. *Arch Intern Med* 1990;150:740-744.
24. Wells HJ, Pagano JF. "Hemoccult" (TM) test-reversal of false-negative results due to storage. *Gastroenterology* 1977;72:1148.
25. Schwartz S, Dahl J, Ellefson M, et al. The HemoQuant test: a specific and quantitative determination of heme (hemoglobin) in feces and other materials. *Clin Chem* 1983;29:2061-2067.
26. Ahlquist DA, McGill DB, Schwartz S, et al. HemoQuant: a new quantitative assay for fecal hemoglobin: comparison with Hemoccult. *Ann Intern Med* 1984;101:297-302.
27. Ahlquist DA, McGill DB, Schwartz S, et al. Fecal blood levels in health and disease: a study using HemoQuant. *N Engl J Med* 1985;312:1422-1428.
28. Ahlquist DA, McGill DB, Fleming JL, et al. Patterns of occult bleeding in asymptomatic colorectal cancers. *Cancer* 1989;63:1826-1830.
29. Joseph AM, Crowson TW, Rich EC. Cost-effectiveness of HemoQuant versus Hemoccult for colorectal cancer screening. *J Gen Intern Med* 1988;3:132-138.
30. St. John DJB, Young GS, Alexeyeff M, et al. Most large and medium colorectal adenomas can be detected by immunochemical occult blood tests. *Gastroenterology* 1990;98(suppl):A312.
31. Songster CL, Barrows GH, Jarrett DP. Immunochemical detection of fecal occult blood—the fecal smear punch-disc test: a noninvasive screening test for colorectal cancer. *Cancer* 1980;45:1099-1102.
32. Bolt RJ. Sigmoidoscopy in detection and diagnosis in the asymptomatic individual. *Cancer* 1971;28:121-122.
33. Frame PS. Screening flexible sigmoidoscopy: is it worthwhile? An opposing view. *J Fam Pract* 1987;25:604-607.
34. Cady N, Persson AV, Monson DO, et al. Changing patterns of colorectal carcinoma. *Cancer* 1974;33:422-426.
35. Rhodes JB, Holmes FF, Clark GM. Changing distribution of primary cancers in the large bowel. *JAMA* 1977;238:1641-1643.
36. Abrams JS, Reines HD. Increasing incidence of right-sided lesions in colorectal cancer. *Am J Surg* 1979;137:522-526.
37. Greene FL. Distribution of colorectal neoplasms. A left-to-right shift of polyps and cancer. *Am J Surg* 1983;49:62-65.
38. Winnan G, Berci G, Panish J, et al. Superiority of the flexible to the rigid sigmoidoscope in routine proctosigmoidoscopy. *N Engl J Med* 1980;302:1011-1012.
39. Bohlman TW, Katon RM, Lipshutz GR, et al. Fiberoptic pansigmoidoscopy: an evaluation and comparison with rigid sigmoidoscopy. *Gastroenterology* 1977;72:644-649.
40. Winawer SJ, Leidner SD, Boyle C, et al. Comparison of flexible sigmoidoscopy with other diagnostic techniques in the diagnosis of rectocolon neoplasia. *Dig Dis Sci* 1979;24:277-281.
41. Marks G, Boggs HW, Castro AF, et al. Sigmoidoscopic examinations with rigid and flexible fiberoptic sigmoidoscopes in the surgeon's office. *Dis Colon Rectum* 1979;22:162-169.

42. Protell RL, Buenger N, Gilbert DA, et al. The short colonoscope: preliminary analysis of a comparison with rigid sigmoidoscopy and Hemoccult testing. *Gastrointest Endosc* 1978;24:208.
43. Nivatvongs S, Fryd DS. How far does the proctosigmoidoscope reach? *N Engl J Med* 1980;303: 380–382.
44. Nicholls RJ, Dube S. The extent of examination by rigid sigmoidoscopy. *Br J Surg* 1982;69:438.
45. Shatz BA, Freitas EL. Area of colon visualized through the sigmoidoscope. *JAMA* 1954;156:717–719.
46. Gillespie PE, Chambers TJ, Chan KW, et al. Colonic adenomas: a colonoscopic survey. *Gut* 1979;20: 240–245.
47. Lehman GA, Buchner DM, Lappas JC. Anatomical extent of fiberoptic sigmoidoscopy. *Gastroenterology* 1983; 84:803–808.
48. Lieberman DA, Smith FW. Screening for colon malignancy with colonoscopy. *Am J Gastroenterol* 1991;86:946–951.
49. Johnson DA, Gurney MS, Volpe RJ, Jones DM, et al. A prospective study of the prevalence of colonic neoplasms in asymptomatic patients with an age-related risk. *Am J Gastroenterol* 1990;85:969–974.
50. Tedesco FJ, Waye JD, Avella JR, Villalobos MM. Diagnostic implications of the spatial distribution of colonic mass lesions (polyps and cancers): a prospective colonoscopic study. *Gastrointest Endosc* 1980;26:95–97.
51. Shinya H, Wolff WI. Morphology, anatomic distribution and cancer potential of colonic polyps: an analysis of 7,000 polyps endoscopically removed. *Ann Surg* 1979;190:679–683.
52. Winawer SJ, Gottlieb LS, Stewart ET, et al. First progress report of the National Polyp Study. *Gastroenterology* 1983;84:1352.
53. Derwin JV. Feasibility of 105-cm flexible sigmoidoscopy in family practice. *J Fam Pract* 1986;23: 341–344.
54. Glick SN, Teplick SK, Balfé DM, et al. Large colonoscopic neoplasms missed by endoscopy. *Am J Radiol* 1989; 152:513–517.
55. Correa P, Strong JP, Reif A, et al. The epidemiology of colorectal polyps: prevalence in New Orleans and international comparisons. *Cancer* 1977;39:2258–2264.
56. Hughes LE. The incidence of benign and malignant neoplasms of the colon and rectum: a postmortem study. *NZ J Surg* 1968;38:30–35.
57. Rickert RR, Auerback O, Garfinke L, et al. Adenomatous lesions of the large bowel: an autopsy survey. *Cancer* 1979;43:1847–1857.
58. Williams AR, Balasoori BAW, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. *Gut* 1982;23:835–842.
59. Muto T, Bussey HJR, Morson BC. The evolution of cancer of the colon and rectum. *Cancer* 1975;36: 2251–2270.
60. Morson BC. Evolution of cancer of the colon and rectum. *Cancer* 1974;34:845–849.
61. Morson BC. The evolution of colorectal carcinoma. *Clin Radiol* 1984;35:425–431.
62. Johnson CD, Carlson HC, Taylor WF, Weiland LP. Barium enemas of carcinoma of the colon: sensitivity of double- and single-contrast studies. *Am J Radiol* 1983;140:1143–1149.
63. Fork FT. Radiographic findings in overlooked colon carcinoma: a retrospective analysis. *Acta Radiol* 1988; 29:331–336.
64. Lang CA, Ransoloff DF. Fecal occult blood screening for colorectal cancer: is mortality reduced by chance selection for screening colonoscopy? *JAMA* 1994;271:1011–1013.
65. Mandel JS, Edwards F, Church T, Bond J. Screening for colorectal cancer: which test is best? [letter]. *JAMA* 1994;272:1099.
66. Selby JV, Friedman GD, Quesenberry CP, Weiss NS. Effect of fecal occult blood testing on mortality from colorectal cancer: a case-control study. *Ann Intern Med* 1993;118:1–6.
67. Wahrendorf J, Robra BP, Wiebelt H, Oberhausen R, Weiland M, Dhom G. Effectiveness of colorectal cancer screening: results from a population-based case-control evaluation in Saarland, Germany. *Eur J Cancer Prev* 1993; 2:221–227.
68. Kronborg O, Fenger C, Sndergaard O, et al. Initial mass screening for colorectal cancer with fecal occult blood test. A prospective randomized study at Funen in Denmark. *Scan J Gastroenterol* 1987;22: 677–686.
69. Hardcastle JD, Thomas WM, Chamberlain J, et al. Randomised, controlled trial of faecal occult blood screening for colorectal cancer: results for first 107,349 subjects. *Lancet* 1989;1:1160–1164.
70. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. *N Engl J Med* 1992;326:653–657.

71. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality. *J Natl Cancer Inst* 1992;84:1572-1575.
72. Cutler JL, Ramcharan S, Feldman R, et al. Multiphasic health evaluation study. 1. Methods and population. *Prev Med* 1973;2:197-206.
73. Dales LG, Friedman GD, Collen MF. Evaluating periodic multiphasic health checkups: a controlled trial. *J Chronic Dis* 1979;32:385-404.
74. Friedman GD, Collen MF, Fireman BH. Multiphasic health evaluation: a 16-year follow-up. *J Chronic Dis* 1986;39:453-463.
75. Selby JV, Friedman GD, Collen MF. Sigmoidoscopy and mortality from colorectal cancer: the Kaiser Permanent Multiphasic Evaluation Study. *J Clin Epidemiol* 1988;41:427-434.
76. Gilbertsen VA. Proctosigmoidoscopy and polypectomy in reducing the incidence of rectal cancer. *Cancer* 1974;34:936-939.
77. Gilbertsen VA, Nelms JM. The prevention of invasive cancer of the rectum. *Cancer* 1978;41: 1137-1139.
78. Hertz REL, Deddish MR, Day E. Value of periodic examinations in detecting cancer of the colon and rectum. *Postgrad Med* 1960;27:290-294.
79. Morrison A. Screening in chronic disease. New York: Oxford University Press, 1985.
80. Nelson RL, Abcarian H, Prasad ML. Iatrogenic perforation of the colon and rectum. *Dis Colon Rectum* 1982; 25:305-308.
81. Waye J, Lewis B, Yessayan S. Colonoscopy: a prospective report of complications. *Gastrointest Endosc* 1990; 36(suppl):A226.
82. MacCarty RL. Colorectal cancer: the case for barium enema. *Mayo Clin Proc* 1992;67:253-257.
83. DiSario JA, Foutch PG, Mai HD, Pardy K, Manne RK. Prevalence and malignant potential of colorectal polyps in asymptomatic, average-risk men. *Am J Gastroenterol* 1991;86:941-945.
84. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. *N Engl J Med* 1993;329:1977-1981.
85. Carroll RLA, Klein M. How often should patients be sigmoidoscoped? A mathematical perspective. *Prev Med* 1980;9:741-746.
86. Sakamoto MS, Hara JH, Schlumpberger JM. Screening flexible sigmoidoscopy in a low-risk, highly screened population. *J Fam Pract* 1994;38:245-248.
87. Atkin WS, Cuzick J, Northover JMA, Whynes DK. Prevention of colorectal cancer by once-only sigmoidoscopy. *Lancet* 1993;341:736-740.
88. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. *N Engl J Med* 1991;325:1593-1596.
89. Kune A, Kune S, Watson LF. Colorectal cancer risk, chronic illness, operations, and medications: case control results from the Melbourne colorectal cancer study. *Cancer Res* 1988;48:4399-4404.
90. Rosenberg L, Balmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. *J Natl Cancer Inst* 1991;83: 355-358.
91. American Cancer Society. Guidelines for the cancer-related checkup: an update. Atlanta: American Cancer Society, 1995.
92. Fleischer DE, Goldberg SB, Browning TH, et al. Detection and surveillance of colorectal cancer. *JAMA* 1989; 261:580-585.
93. American College of Obstetricians and Gynecologists. Routine cancer screening. Committee Opinion no. 128. Washington, DC: American College of Obstetricians and Gynecologists, 1993.
94. Ferrucci JT. Screening for colon cancer: programs of the American College of Radiology. *Am J Radiol* 1993;160:999-1003.
95. American Academy of Family Physicians. Age charts for periodic health examination. Kansas City, MO: American Academy of Family Physicians, 1994. (Reprint no. 510.)
96. Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive health care. Ottawa: Canada Communication Group, 1994:797-809.
97. Greenwald P. Colon cancer overview. *Cancer* 1992;70:1206-1215.
98. Blalock SJ, DeVellis BM, Sandler RS. Participation in fecal occult blood screening: a critical review. *Prev Med* 1987;16:9-18.
99. Elwood TW, Erickson A, Lieberman S. Comparative educational approaches to screening for colorectal cancer. *Am J Public Health* 1978;68:135-138.

100. Winchester DP, Shull JH, Scanlon EF, et al. A mass screening program for colorectal cancer using chemical testing for occult blood in the stool. *Cancer* 1980;45:2955–2958.
101. Ahlquist DA. Occult blood screening: obstacles to effectiveness. *Cancer* 1992;70:1259–1265.
102. Winawer SJ, Miller C, Lightdale C, et al. Patient response to sigmoidoscopy: a randomized, controlled trial of rigid and flexible sigmoidoscopy. *Cancer* 1987;60:1905–1908.
103. Petravage J, Swedberg J. Patient response to sigmoidoscopy recommendations via mailed reminders. *J Fam Pract* 1988;27:387–389.
104. Holt WS. Factors affecting compliance with screening sigmoidoscopy. *J Fam Pract* 1991;32:585–589.
105. Launoy G, Veret JL, Richir B, et al. Involvement of general practitioners in mass screening: experience of a colorectal cancer mass screening programme in the Calvados region (France). *Eur J Cancer Prev* 1993;2:229–232.
106. Shapiro M. Flexible fiberoptic sigmoidoscopy: the long and the short of it. *Gastrointest Endosc* 1984;30:114–116.
107. Griffin JW. Flexible fiberoptic sigmoidoscopy: longer may not be better for the nonendoscopist. *Gastrointest Endosc* 1985;31:347–348.
108. Weissman GS, Winawer SJ, Baldwin MP, et al. Multicenter evaluation of training of nonendoscopists in flexible sigmoidoscopy. *CA Cancer J Clin* 1987;37:26–30.
109. Clayman CB. Mass screening for colorectal cancer: are we ready? *JAMA* 1989;261:609.
110. Frank JW. Occult-blood screening for colorectal carcinoma: the yield and the costs. *Am J Prev Med* 1985;1:18–24.
111. Ransohoff DF, Lang CA. Screening for colorectal cancer. *N Engl J Med* 1991;325:37–41.
112. Wagner J. From the Congressional Office of Technology Assessment: costs and effectiveness of colorectal cancer screening in the elderly. *JAMA* 1990;264:2732.
113. Lynch HT, Watson P, Smyrk TC, et al. Colon cancer genetics. *Cancer* 1992;70:1300–1312.

DR. RUPNATHJI (DR. RUPNATHJI)